MENU
+Compare
MDGL
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$432.89
Change
+$1.68 (+0.39%)
Capitalization
9.65B

MDGL Madrigal Pharmaceuticals Forecast, Technical & Fundamental Analysis

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality... Show more

MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MDGL with price predictions
Sep 05, 2025

Aroon Indicator for MDGL shows an upward move is likely

MDGL's Aroon Indicator triggered a bullish signal on September 05, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator showed a similar pattern. In of the 161 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for MDGL moved above the 200-day moving average on August 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.812) is normal, around the industry mean (20.107). P/E Ratio (0.000) is within average values for comparable stocks, (52.767). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.138). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (18.382) is also within normal values, averaging (327.388).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MDGL is expected to report earnings to rise 5.26% to -200 cents per share on October 30

Madrigal Pharmaceuticals MDGL Stock Earnings Reports
Q3'25
Est.
$-2.00
Q2'25
Beat
by $1.73
Q1'25
Beat
by $0.54
Q4'24
Beat
by $1.77
Q3'24
Beat
by $1.84
The last earnings report on August 05 showed earnings per share of -189 cents, beating the estimate of -363 cents. With 281.20K shares outstanding, the current market capitalization sits at 9.65B.
A.I. Advisor
published General Information

General Information

a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
200 Barr Harbor Drive
Phone
+1 267 824-2827
Employees
276
Web
http://www.madrigalpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGFEX83.010.20
+0.24%
American Funds Growth Fund of Amer 529E
JOEAX13.90N/A
N/A
JOHCM Emerging Markets Opps Investor
DRESX25.19N/A
N/A
Driehaus Emerging Markets Small Cap Gr
GFCUX24.30N/A
N/A
Goldman Sachs Enhanced U.S. Equity R6
LAMSX24.83N/A
N/A
Lord Abbett Dividend Growth R4

MDGL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.39%
ALXO - MDGL
56%
Loosely correlated
+12.96%
NAGE - MDGL
45%
Loosely correlated
+0.97%
IPHA - MDGL
44%
Loosely correlated
-2.20%
RNAC - MDGL
43%
Loosely correlated
+6.40%
GHRS - MDGL
43%
Loosely correlated
+0.28%
More